Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01472627 · ClinicalTrials.gov registry record
Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro
A clinical trial, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- 11
- Enrollment target
NCT01472627 is a clinical trial that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 11 participants.
The verdict
NCT01472627 has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- 11 participants
- Enrollment target
Study Summary
The purpose of this study is to better understand what effects Bortezomib, a drug used for multiple myeloma therapy, has on the immune system.
Interventions
- PROCEDURE Blood draws
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2010-10 |
| Est. Completion | 2018-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01472627
The ClinicalTrials.gov registry entry for NCT01472627 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Blood draws is the first listed.
NCT01472627 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01472627 about?
NCT01472627 is a clinical study titled "Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro". The purpose of this study is to better understand what effects Bortezomib, a drug used for multiple myeloma therapy, has on the immune system.
What is the current status of trial NCT01472627?
This trial is currently completed. The enrollment target is 11 participants. The study started on 2010-10. Estimated completion is 2018-01.
What interventions are being tested in trial NCT01472627?
The interventions under investigation include: Blood draws (PROCEDURE).
Who is sponsoring clinical trial NCT01472627?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.